CN1679857A - Chinese medicine composition for treating lithiasis and preparation thereof - Google Patents
Chinese medicine composition for treating lithiasis and preparation thereof Download PDFInfo
- Publication number
- CN1679857A CN1679857A CN 200510049219 CN200510049219A CN1679857A CN 1679857 A CN1679857 A CN 1679857A CN 200510049219 CN200510049219 CN 200510049219 CN 200510049219 A CN200510049219 A CN 200510049219A CN 1679857 A CN1679857 A CN 1679857A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- chinese medicine
- medicine composition
- decocted
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 46
- 208000015924 Lithiasis Diseases 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 title claims description 24
- 238000002360 preparation method Methods 0.000 title description 3
- 241000218176 Corydalis Species 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000008187 granular material Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 241000237636 Pheretima Species 0.000 claims description 10
- 241000222640 Polyporus Species 0.000 claims description 10
- 210000003038 endothelium Anatomy 0.000 claims description 10
- 210000000582 semen Anatomy 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 238000005325 percolation Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000005516 engineering process Methods 0.000 claims description 5
- 241000241550 Cyathula Species 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 3
- 238000005457 optimization Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 abstract description 6
- 206010029148 Nephrolithiasis Diseases 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 2
- 239000002245 particle Substances 0.000 abstract description 2
- 235000008499 Canella winterana Nutrition 0.000 abstract 1
- 244000080208 Canella winterana Species 0.000 abstract 1
- 241000737263 Lygodium Species 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 229940017545 cinnamon bark Drugs 0.000 abstract 1
- 238000000151 deposition Methods 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000000913 Kidney Calculi Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000626 ureter Anatomy 0.000 description 3
- 208000031868 Calculus ureteric Diseases 0.000 description 2
- 206010009866 Cold sweat Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 208000000014 Ureteral Calculi Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- XEEVLJKYYUVTRC-UHFFFAOYSA-N oxomalonic acid Chemical compound OC(=O)C(=O)C(O)=O XEEVLJKYYUVTRC-UHFFFAOYSA-N 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000011086 ureterolithiasis Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Abstract
A Chinese medicine in the form of particles for treating nephrolithiasis and the lithiasis in urinary system is prepared from 11 Chinese-medicinal materials including lygodium spores, corydalis tuber, earthworm, cinnamon bark, etc through proportional mixing, pulverizing, immersing, seeping, decocting, filtering, depositing, concentrating, granulating and drying.
Description
Technical field
The invention belongs to the Chinese medicine preparation technical field, be specifically related to a kind of Chinese medicine composition and production method thereof for the treatment of lithiasis.
Background technology
Renal calculus is one of clinical common disease, brings very big misery to patient, the uralyt of the medicine of existing treatment renal calculus such as oral lithagogue liquid, Germany etc., all be cholelithiasis and urinary system calculus unification treatment, both obscure mutually, and curative effect is not single-minded, and unsatisfactory curative effect; Some lithagogue infusions and for example, the dose in its prescription, the composition and the pharmacological action of medicine are undesirable, and curative effect is not good enough.
Present Therapeutic Method has western medicine therapy and tcm therapy, doctor trained in Western medicine mainly is to treat by operation or with the method for laser lithotripsy, for patient, mostly be unwilling unless it is absolutely necessary to perform an operation, some patient's health is unfit to do operation, often due to illness feelings recur and cause pain, can only be by taking medicine pain relieving and antiinflammatory; The laser lithotripsy method has certain danger, in case the treatment failure, consequence is hardly imaginable, and a lot of patients are unwilling to accept this Therapeutic Method.Now, there is more patient to be ready to adopt the traditional tcm therapy of China, promptly comes fossil, calculus, to reach the purpose of treatment by taking Chinese medicine.Yet existing herbal treatment has certain effect to less calculus, and effect was just relatively poor when calculus was big slightly, traces it to its cause, and crucial still Chinese medicine preparation is unreasonable, causes the curative effect of Chinese medicine aspect fossil can't reach satisfactory result.
Summary of the invention
The objective of the invention is to overcome problems of the prior art, provide a kind of compatibility reasonable, and to treating the technical scheme of more efficiently Chinese medicine composition of lithiasis and production method thereof.
The Chinese medicine composition of described treatment lithiasis is characterized in that by comprising that following raw materials by weight proportions makes:
Herba Glechomae 14～22 Spora Lygodii 5～13 Rhizoma Corydalis 1～9 Radix Cyathulae 5～13
Semen Abutili 7～15 Pheretimas 2～10 Endothelium Corneum Gigeriae Galli 5～13 Cortex Cinnamomis 1～9
Radix Glycyrrhizae uralensis 2～10 Polyporus 7～15 Rhizoma Alismatis 7～15
Described Chinese medicine composition is characterized in that wherein the optimization proportioning of each crude drug is:
Herba Glechomae 16～20 Spora Lygodii 7～11 Rhizoma Corydalis 3～7 Radix Cyathulaes 7～1
Semen Abutili 9～13 Pheretimas 4～8 Endothelium Corneum Gigeriae Galli 7～11 Cortex Cinnamomis 3～7
Radix Glycyrrhizae uralensis 4～8 Polyporus 9～13 Rhizoma Alismatis 9～13
The production method of above-mentioned Chinese medicine composition is characterized in that comprising following processing step:
(a) with the Rhizoma Corydalis and the Cortex Cinnamomi of described weight proportion, break into coarse grain, moistening with 55-65% ethanol, flooded 46-50 hour, the ethanol of doubly measuring with 6-10 carries out percolation, collects percolate;
(b) medicinal residues behind Herba Glechomae, Spora Lygodii, Radix Cyathulae, Semen Abutili, Pheretima, Endothelium Corneum Gigeriae Galli, Radix Glycyrrhizae uralensis, Polyporus, Rhizoma Alismatis and the last step percolation of described weight proportion are decocted with water secondary, for the first time adding water 8-12 doubly measures, decocted 1.5-2.5 hour, for the second time adding water 6-10 doubly measures, decocted 1.5-2.5 hour, and merged decoction liquor;
(c) decoction liquor is filtered, and it is 1.15-1.20 that filtrate is concentrated into 58-62 ℃ of relative density;
(d) add ethanol to ethanol content in above-mentioned concentrated solution and reach 66-74%, staticly settled 46-50 hour, filter, merging filtrate and (a) step percolate reclaim ethanol, and to be concentrated into 58-62 ℃ of relative density be 1.05-1.10;
(e) technology routinely adds dextrin and correctives in (d) step gained concentrated solution, spray drying gets fine powder, granulates, dry, packing.
The proportioning that the present invention relates to is weight proportion.
Above-mentioned Chinese medicine composition is used for the calculus of urinary system of damp-heat accumulation, caused by energy stagnation and blood stasis, has effects such as clearing away heat-damp and promoting diuresis, regulating qi to disperse stagnation, calculus pain relieving.This Chinese medicine composition can improve the specificity of medication greatly, and curative effect of medication of other treatment congenerous disease has large increase relatively, and, the present invention's uniqueness of filling a prescription, evident in efficacy, production method is simple.
The specific embodiment
Example formulations:
Herba Glechomae 18 Spora Lygodii 9 Rhizoma Corydalis 5 Radix Cyathulaes 9
Semen Abutili 11 Pheretimas 6 Endothelium Corneum Gigeriae Galli 9 Cortex Cinnamomis 5
Radix Glycyrrhizae uralensis 6 Polyporus 11 Rhizoma Alismatis 11
This Chinese medicine composition makes according to following process by above-mentioned prescription:
(a) with the Rhizoma Corydalis and the Cortex Cinnamomi of described weight proportion, break into coarse grain, moistening with 60% ethanol, flooded 48 hours, carry out percolation with the ethanol of 8 times of amounts, collect percolate;
(b) medicinal residues behind Herba Glechomae, Spora Lygodii, Radix Cyathulae, eastern certain herbaceous plants with big flowers, Pheretima, Endothelium Corneum Gigeriae Galli, Radix Glycyrrhizae uralensis, Polyporus, Rhizoma Alismatis and the percolation of described weight proportion are decocted with water secondary, for the first time add 10 times of amounts of water, decocted 2 hours, add 8 times of amounts of water for the second time, decocted 2 hours, and merged decoction liquor;
(c) decoction liquor is filtered, and filtrate is concentrated into 60 ℃ of relative density 1.15-1.20;
(d) add ethanol to ethanol content in above-mentioned concentrated solution and reach 70%, staticly settled 48 hours, filter, merging filtrate and percolate reclaim ethanol, and to be concentrated into 60 ℃ of relative densities be 1.05-1.10;
(e) technology routinely adds dextrin and correctives in (d) step gained concentrated solution, spray drying gets fine powder, granulates, dry, packing.
The function of this Chinese medicine composition: clearing away heat-damp and promoting diuresis, regulating qi to disperse stagnation, calculus pain relieving; Cure mainly: the calculus of urinary system of damp-heat accumulation, caused by energy stagnation and blood stasis; Suggestion instructions about how to take medicine and consumption: 30g/ day, divide and take after mixing it with water for 3 times.
Below further sets forth the beneficial effect of Chinese medicine composition of the present invention by testing example, these tests have comprised that the routine and clinical observation on the therapeutic effect of the pharmacodynamics test of Chinese medicine composition of the present invention (leading to clever granule to call in the following text) tests.
Pharmacodynamic test of active extract result
Test according to a conventional method, the result shows that oral logical clever granule 10g/kg, 20g/kg, 40g/kg cause the rat urinary system calculus to oxalamide and have prevention and therapeutical effect, the incidence rate of the calculus of kidney, ureter and bladder is significantly reduced, the area of nephridial tissue mesoxalic acid and calcium content and calcium oxalate crystal obviously reduces, and dose relationship is clear and definite.External, logical clever particle solution has stronger solvability to calcium oxalate, and logical clever granule also has tangible hydrotropy effect to calcium salt in people's renal calculus.Logical clever granule 10g/kg, 20g/kg, 40g/kg have tangible diuresis to water load rat, and obviously increase the dissolubility of rat urine calcium oxalate.In addition, logical clever granule obviously suppresses the mice ear degree due to the dimethylbenzene, reduces lumbar injection acetic acid and causes the mouse writhing reaction times, and prompting this product has certain antiinflammatory and analgesic activity.The rat urinary system calculus that The above results prompting Chinese medicine composition of the present invention can obviously prevent and treat oxalamide to cause, its mechanism of action may be relevant with the dissolving that increases urine amount, promotion calculus composition, and experiment simultaneously finds that also Chinese medicine composition of the present invention has certain analgesia and antiinflammatory action.
Logical clever granule mice mtd test
Test material: anthology invention medicine leads to clever granule.
Test method: the oral logical clever granule suspension 40ml/kg that contains crude drug 8g/ml of ICR mice, totally 2 times, there is not tangible acute toxic reaction, there is not dead mouse in 14 days, the mice body weight all rises appreciably.
Conclusion: lead to clever granule mice maximum dosage-feeding 640g/kg, be equivalent to 226 times of the clinical consumption of people.
Logical clever granule rat long term toxicity test
120 of SD rats are adopted in this test, are divided into 4 groups, and 30 every group, male and female half and half, dosage is respectively 120,60 and 30g/kg, is equivalent to 42,21 and 10.5 times of clinical recommendation consumption respectively, and other establishes the ordinary water matched group, continuously 6 months (26 week) of gastric infusion.
The result shows:
Logical each dosage group of clever granule does not have obvious influence to the female rats body weight gain in whole experiment periods, heavy dose of group male rat the 9th, 10 all weight ratio matched groups are lower slightly, other the time respectively organize the body weight no significant difference mutually; Heavy dose of the 7th week of group of logical clever granule, middle dosage group the 8th and the feed of 18 weeks slightly reduce, other the time respectively organize no significant difference mutually; The phase amount of drinking water is all than matched group height when major part for each group of administration, but amplitude is little, and wherein heavy dose of and small dose group the 9th and 10 all differences have significance.Each group of experimental session administration does not have obvious influence to general situations such as activities in rats.
Administration is during 13 weeks, and the HGB of logical each dosage group of clever granule is all than matched group height, and mid-term is slightly low than matched group again, and convalescent period is respectively organized no significant difference; 13 all small dose group leukocyte counts slightly reduce; Other each index is respectively organized no significant difference.The prompting medicine there is no obvious harmful effect to the rat serum conventional index.
The ALT level of logical each dosage group of clever granule is all obviously low than matched group when administration 13 and 26 weeks, small dose group during 13 weeks AST also low than matched group; Administration 26 during week in dosage TBI be starkly lower than matched group, the BUN of dosage group is than matched group height in convalescent period; Other each main biochemical indicator and compare no significant difference.The prompting medicine is to the main biochemical indicator of rat blood serum and have no adverse effects.
13 weeks of administration, 26 weeks and convalescent period are led to main organs weight and the equal no significant difference of matched group of each dosage group rat of clever granule.
Each administration group of important organ Microscopic examination showed all has indivedual rat pulmonary that slight interstitial pneumonia is arranged, but does not have dose relationship, may be that idol has medicine to choke into causing in the administration process, and matched group also has analogue and drug toxicity to there is no obvious relation.Other main organs comprise all Non Apparent Abnormalities such as the heart, liver,kidney,spleen, brain, stomach, thymus, adrenal gland, testis, epididymis, prostate, seminal vesicle, uterus and ovary.The prompting medicine does not have obvious harmful effect to the morphosis of rat important organ.
The above results prompting is under this experiment condition and the dosage selected for use, and logical clever granule long term administration does not have tangible toxic reaction to rat.
The clinical observation of traditional Chinese medicine composition for treating lithiasis of the present invention
1) patient, man, 40 years old.Clinical diagnosis: frequent micturition, urgent micturition, pain are squatted down and are curled unbearably, and dripping sweat is on tenterhooks, and pale complexion is with feeling sick, vomitting.During inspection, patient's waist obviously tunks pain, through laboratory urine examination erythrocyte +++, leukocyte+.Ultrasound diagnosis prompting: left kidney inferior calyx calculus.Heavy real, the string of patient's pulse condition, yellow, greasy and thin fur, damp-heat in lower-JIAO pents up, and controls suitable clearing away heat-damp and promoting diuresis silt, calculus is treating stranguria.Therapeutic Method: by drug prescription of the present invention, 1 dose of every day takes after mixing it with water.Therapeutic outcome: after taking 12 doses, discharge two pieces in 0.8 * 1.0cm, 0.5 * 0.7cm calculus, patient's frequent micturition, urgent micturition, the complete obiteration of pain in the lumbar region pain, city-level hospital B ultrasonic is checked left kidney does not once more have the discovery stone-echo.
2) patient, woman, 32 years old.Clinical diagnosis: left side waist angor, with frequent micturition, urgent micturition, sometimes urinate and interrupt suddenly, activity can continue to urinate a little, simultaneously, the violent angor of left abdomen paroxysmal, locate radiation with femoribus internus etc., squat down and curl, be on tenterhooks, pain repeatedly several times, angor is violent, with nausea and vomiting, is in a cold sweat.The urine examination of auxiliary section office, erythrocyte as a result through the city-level the People's Hospital +++, small quantities of leukocytes, the ultrasound diagnosis prompting: the left side ureteral calculus with left kidney moderate hydrops, is diagnosed as left ureter upper end calculus.Heavy real, the string of patient's pulse condition, yellow, greasy and thin fur, damp-heat in lower-JIAO pents up, and hematuria then appears in the damp and hot blood network that injures, and in addition because of damp-heat accumulation, sandstone stops urinary tract, blocks the circulation of mechanism of qi and urine, controls suitable clearing away heat-damp and promoting diuresis, Tonglin Paishi.Therapeutic Method: by drug prescription of the present invention, 1 dose of every day takes after mixing it with water.Therapeutic outcome: after taking 9 doses, discharge two pieces of the big microliths of Semen Glycines, patient's transference cure goes to city-level hospital to do the B ultrasonic check once more, does not have the kidney district of discovery and ureter road stone-echo.
3) patient, man, 42 years old.Clinical diagnosis: the burst right side has a excruciating pain in the belly, the outstanding play of button, and pain very then cold sweat is let out greatly, cyanosis of the lips and nails, little distention and fullness in the abdomen, urine is anxious frequently, urinates color as washing the water of meat, is hard and dry, and pulse condition is heavy real, the rich mutually stone of forming mutually of yellow, greasy and thin fur, damp-heat in lower-JIAO and blood.The sick stranguria caused by urinary stone that belongs to of patient is controlled suitable heat clearing away blood stasis expelling, Tonglin Paishi.Patient's lumbago is acutely up to the emergency treatment of the People's Hospital, Linan, the urine examination erythrocyte +++, leukocyte+, the B ultrasonic prompting: there are one 1 * 1.5cm and the big microlith of 0.6 * 0.8cm in defeated pipe upper end, right side, is diagnosed as " lithangiuria ".Therapeutic Method: by drug prescription of the present invention, 1 dose of every day takes after mixing it with water.Therapeutic outcome: after taking 15 doses, urine is discharged two pieces in calculus, and all diseases disappear.
Above numerical example, clinical manifestation has nothing in common with each other, but from differential diagnosis in tcm examine because of, congestion this factor of causing a disease is all arranged.Congestion is the pathological product that causes owing to different reasons, and then becomes a paathogenic factor that influences internal organs meridian qi and blood functional disorder.Above-mentioned for this reason numerical example has all used the activating blood circulation to dissipate blood stasis method clinically, cooperates other methods in conjunction with the congestion origin cause of formation again simultaneously, can bring into play its effect better.
Claims (5)
1, the Chinese medicine composition of treatment lithiasis is characterized in that by comprising that following raw materials by weight proportions makes:
Herba Glechomae 14～22 Spora Lygodii 5～13 Rhizoma Corydalis 1～9 Radix Cyathulae 5～13
Semen Abutili 7～15 Pheretimas 2～10 Endothelium Corneum Gigeriae Galli 5～13 Cortex Cinnamomis 1～9
Radix Glycyrrhizae uralensis 2～10 Polyporus 7～15 Rhizoma Alismatis 7～15.
2, Chinese medicine composition as claimed in claim 1 is characterized in that wherein the optimization proportioning of each crude drug is:
Herba Glechomae 16～20 Spora Lygodii 7～11 Rhizoma Corydalis 3～7 Radix Cyathulaes 7～11
Semen Abutili 9～13 Pheretimas 4～8 Endothelium Corneum Gigeriae Galli 7～11 Cortex Cinnamomis 3～7
Radix Glycyrrhizae uralensis 4～8 Polyporus 9～13 Rhizoma Alismatis 9～13.
3, Chinese medicine composition as claimed in claim 1 is characterized in that wherein the best proportioning of each crude drug is:
Herba Glechomae 18 Spora Lygodii 9 Rhizoma Corydalis 5 Radix Cyathulaes 9
Semen Abutili 11 Pheretimas 6 Endothelium Corneum Gigeriae Galli 9 Cortex Cinnamomis 5
Radix Glycyrrhizae uralensis 6 Polyporus 11 Rhizoma Alismatis 11.
4,, it is characterized in that comprising following processing step as the production method of the described Chinese medicine composition of claim 1-3:
(a) with the Rhizoma Corydalis and the Cortex Cinnamomi of described weight proportion, break into coarse grain, moistening with 55-65% ethanol, flooded 46-50 hour, the ethanol of doubly measuring with 6-10 carries out percolation, collects percolate;
(b) medicinal residues behind Herba Glechomae, Spora Lygodii, Radix Cyathulae, Semen Abutili, Pheretima, Endothelium Corneum Gigeriae Galli, Radix Glycyrrhizae uralensis, Polyporus, Rhizoma Alismatis and the last step percolation of described weight proportion are decocted with water secondary, for the first time adding water 8-12 doubly measures, decocted 1.5-2.5 hour, for the second time adding water 6-10 doubly measures, decocted 1.5-2.5 hour, and merged decoction liquor;
(c) decoction liquor is filtered, and it is 1.15-1.20 that filtrate is concentrated into 58-62 ℃ of relative density;
(d) add ethanol to ethanol content in above-mentioned concentrated solution and reach 66-74%, staticly settled 46-50 hour, filter, merging filtrate and (a) step percolate reclaim ethanol, and to be concentrated into 58-62 ℃ of relative density be 1.05-1.10;
(e) technology routinely adds dextrin and correctives in (d) step gained concentrated solution, spray drying gets fine powder, granulates, dry, packing.
5, the production method of Chinese medicine composition as claimed in claim 4 is characterized in that comprising following processing step:
(a) with the Rhizoma Corydalis and the Cortex Cinnamomi of described weight proportion, break into coarse grain, moistening with 60% ethanol, flooded 48 hours, carry out percolation with the ethanol of 8 times of amounts, collect percolate;
(b) medicinal residues behind Herba Glechomae, Spora Lygodii, Radix Cyathulae, Semen Abutili, Pheretima, Endothelium Corneum Gigeriae Galli, Radix Glycyrrhizae uralensis, Polyporus, Rhizoma Alismatis and the percolation of described weight proportion are decocted with water secondary, for the first time add 10 times of amounts of water, decocted 2 hours, add 8 times of amounts of water for the second time, decocted 2 hours, and merged decoction liquor;
(c) decoction liquor is filtered, and filtrate is concentrated into 60 ℃ of relative density 1.15-1.20;
(d) add ethanol to ethanol content in above-mentioned concentrated solution and reach 70%, staticly settled 48 hours, filter, merging filtrate and percolate reclaim ethanol, and to be concentrated into 60 ℃ of relative densities be 1.05-1.10;
(e) technology routinely adds dextrin and correctives in (d) step gained concentrated solution, spray drying gets fine powder, granulates, dry, packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510049219A CN100592916C (en) | 2005-01-26 | 2005-01-26 | Chinese medicine composition for treating lithiasis and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510049219A CN100592916C (en) | 2005-01-26 | 2005-01-26 | Chinese medicine composition for treating lithiasis and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1679857A true CN1679857A (en) | 2005-10-12 |
| CN100592916C CN100592916C (en) | 2010-03-03 |
Family
ID=35066863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200510049219A Expired - Fee Related CN100592916C (en) | 2005-01-26 | 2005-01-26 | Chinese medicine composition for treating lithiasis and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100592916C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872437A (en) * | 2012-09-27 | 2013-01-16 | 强红兵 | Special-disease calculus-removing decoction for treating renal calculus |
| CN104306737A (en) * | 2014-11-09 | 2015-01-28 | 朱海燕 | Traditional Chinese medicine composition for treating kidney calculi as well as preparation method and application thereof |
| CN105943664A (en) * | 2016-06-27 | 2016-09-21 | 杨大妹 | Traditional Chinese medicine for treating urolithiasis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1056775C (en) * | 1997-01-13 | 2000-09-27 | 李国华 | Drug for curing stone of urinary system |
-
2005
- 2005-01-26 CN CN200510049219A patent/CN100592916C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872437A (en) * | 2012-09-27 | 2013-01-16 | 强红兵 | Special-disease calculus-removing decoction for treating renal calculus |
| CN102872437B (en) * | 2012-09-27 | 2014-09-17 | 强红兵 | Special-disease calculus-removing decoction for treating renal calculus |
| CN104306737A (en) * | 2014-11-09 | 2015-01-28 | 朱海燕 | Traditional Chinese medicine composition for treating kidney calculi as well as preparation method and application thereof |
| CN105943664A (en) * | 2016-06-27 | 2016-09-21 | 杨大妹 | Traditional Chinese medicine for treating urolithiasis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100592916C (en) | 2010-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1742903A (en) | Medicine for treating prostatitis and hyperlasia of prostate | |
| CN100592916C (en) | Chinese medicine composition for treating lithiasis and preparation thereof | |
| CN104623196A (en) | Traditional Chinese medicinal composition used for treating chronic nephritis as well as preparation method and application thereof | |
| CN1806835A (en) | Pharmaceutical composition for treating cerebral hemorrhage and its preparation method | |
| CN100344299C (en) | Medicine for treating woman's dysmenorrhea and preparing process thereof | |
| CN100384462C (en) | Medicinal composition for treating acute urarthritis and its preparation method | |
| CN1712055A (en) | Chinese medicinal preparation (litholytic capsule) for treating urinific calculus | |
| CN100434112C (en) | Pure Chinese medicine for treating hyperplasia of mammary glands and preparing method | |
| CN1876088A (en) | A medicine for treating chronic prostatitis and preparation method thereof | |
| CN1134298A (en) | "Dianxianningxiwan" pills-Chinese patent medicine for epilepsy | |
| CN101028349A (en) | Externally-applied medicine for treating prostatitis and prostatic accrementition | |
| CN1246024C (en) | Prepared Chinese medicine for treating acute and chronic urinary infection | |
| CN105434915A (en) | Pharmaceutical composition for treating urolithiasis for dogs and cats and preparation method of pharmaceutical composition | |
| CN1176690C (en) | Medicine for treating chronic nephritis | |
| CN1836703A (en) | Medicine for treating acute urinary tract infection and its preparing method | |
| CN1686272A (en) | Medicine for treating chronic prostatitis and its preparation method | |
| CN1772239A (en) | Chinese medicine prepn for treating vaginitis and cervicitis | |
| CN1183952C (en) | Medicine for treating uterus myoma disease and its preparation method | |
| CN1259943C (en) | Prostate hyperplasia pharmaceutical and method for making same | |
| CN113876864B (en) | Pharmaceutical composition for treating infertility and preparation method and application thereof | |
| CN100342879C (en) | Liver fibrosis treating prepn and its process | |
| CN117442677B (en) | Pharmaceutical composition for kidney injury and preparation method and application thereof | |
| CN1548065A (en) | Compound Chinese medicine for treating chronic pulvic infection and prepn process of its prepn forms | |
| CN103055192B (en) | Women inflammation recovery chewable tablet | |
| CN1253163C (en) | Medicinal composition for preventing and treating hyperplasia of prostate and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XINFU PHARMACEUTICAL IND CO., LTD., HANGZHOU Effective date: 20070907 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070907 Address after: 311300 Jin Town, Hangzhou City, Zhejiang, Ling'an Applicant after: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. Address before: 311305 Ling'an Economic Development Zone, Zhejiang, Hangzhou Applicant before: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 311300 Jin Town, Hangzhou City, Zhejiang, Ling'an Patentee after: YIFAN XINFU PHARMACEUTICAL Co.,Ltd. Address before: 311300 Jin Town, Hangzhou City, Zhejiang, Ling'an Patentee before: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20160623 Address after: 311300 Zhejiang province Hangzhou city Ling'an City Jin Nan Street Shang Gua 9 Patentee after: HANGZHOU XINFU SCIENCE & TECHNOLOGY Co.,Ltd. Address before: 311300 Jin Town, Hangzhou City, Zhejiang, Ling'an Patentee before: YIFAN XINFU PHARMACEUTICAL Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100303 Termination date: 20210126 |